Catalent NYSE CTLT
$56.45 -0.03 -0.05%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 15 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

10.28B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

14.71B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

1.39
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

182.00M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

25.71 %
Upcoming events Catalent All events
No upcoming events scheduled

Stock chart Catalent

Stock analysis Catalent

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-16.99 26.72
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
2.22 5.29
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
68.72 17.44
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
20.69 1.38
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-16.41 20.60

Price change Catalent per year

86.43$ 142.64$
Min Max

Summary analysis Catalent

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Catalent

Revenue and net income Catalent

All parameters
Stock news Catalent All news

Catalent Swings to 2Q Loss on Lower Sales After Covid Programs Fade

Catalent Swings to 2Q Loss on Lower Sales After Covid Programs Fade

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 3rd Update

Novo Holdings to Buy Catalent for $11.5 Billion in Cash -- 3rd Update

S&P 500 Futures Decline in Premarket Trading; Estee Lauder, Catalent Lead

Novo Holdings to Buy Catalent in $16.5 Billion Deal -- 2nd Update

Novo Holdings to Buy Catalent in $16.5 Billion Deal -- 2nd Update

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk

Novo Nordisk’s controlling shareholder to buy Catalent for $16.5 billion

Novo Nordisk Buys Manufacturing Sites as Part of Novo Holdings' Acquisition of Catalent

Novo Nordisk Buys Manufacturing Sites as Part of Novo Holdings' Acquisition of Catalent

Novo Holdings Buying Catalent in $16.5 Billion Deal

Novo Nordisk’s controlling shareholder to buy Catalent for $16.5 billion

Catalent Shares Rise After Providing FY24 Outlook From GLP-1 Drugs

Catalent Shares Rise After Providing FY24 Outlook From GLP-1 Drugs

Catalent Revises 4Q23, 1Q24 Results

Catalent Revises 4Q23, 1Q24 Results

S&P 500 Futures Rise in Premarket Trading; Target, Catalent Lead

Catalent 1Q Revenue Declines, Sees Loss

About company Catalent

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Address:
14 Schoolhouse Road, Somerset, NJ, United States, 08873
Company name: Catalent
Issuer ticker: CTLT
ISIN: US1488061029
Country: USA
Exchange: NYSE
Currency: $
IPO date: 2014-07-31
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.catalent.com

On which stock exchange are Catalent (CTLT) stocks traded?

Catalent (CTLT) stocks are traded on NYSE.

What is the ticker of Catalent stocks (CTLT)?

The stock ticker of Catalent’s stocks or in other words, the code is CTLT. The stocks are currently listed on the NYSE exchange.

In which sector and industry does Catalent (CTLT) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Catalent (CTLT) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Catalent (CTLT) stocks traded?

Catalent (CTLT) stocks are traded on the NYSE exchange in dollars.

What is the price of Catalent (CTLT) stocks today?

The current price of Catalent stocks on 29.03.2024 is 56.45 dollars. per share.

What is the dynamics of Catalent (CTLT) stocks from the beginning of the year?

Catalent (CTLT) quotes have increased by 25.31% from the beginning of the year up to 56.45 dollars. per 1 stocks.

How much did Catalent (CTLT) stocks increase in марте 2024?

This month Catalent (CTLT) quotes have increased by -1.29% to 56.45 dollars. per share.

How much are Catalent (CTLT) stocks worth?

Today, on October, 29.03.2024 Catalent’s (CTLT) stocks cost 56.45 dollars..

What is the market capitalization of Catalent (CTLT)?

Capitalization is the market value of Catalent (CTLT) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 29.03.2024, the market capitalization of Catalent (CTLT) is estimated at about 10279360000 dollars.